GATA2 deficiency and related myeloid neoplasms.
Identifieur interne : 000538 ( Main/Exploration ); précédent : 000537; suivant : 000539GATA2 deficiency and related myeloid neoplasms.
Auteurs : Marcin W. Wlodarski [Allemagne] ; Matthew Collin [Royaume-Uni] ; Marshall S. Horwitz [États-Unis]Source :
- Seminars in hematology [ 1532-8686 ] ; 2017.
Abstract
The GATA2 gene codes for a hematopoietic transcription factor that through its two zinc fingers (ZF) can occupy GATA-DNA motifs in a countless number of genes. It is crucial for the proliferation and maintenance of hematopoietic stem cells. During the past 5 years, germline heterozygous mutations in GATA2 were reported in several hundred patients with various phenotypes ranging from mild cytopenia to severe immunodeficiency involving B cells, natural killer cells, CD4(+) cells, monocytes and dendritic cells (MonoMAC/DCML), and myeloid neoplasia. Some patients additionally show syndromic features such as congenital deafness and lymphedema (originally defining the Emberger syndrome) or pulmonary disease and vascular problems. The common clinical denominator in all reported cohorts is the propensity for myeloid neoplasia (myelodysplastic syndrome [MDS], myeloproliferative neoplasms [MPN], chronic myelomonocytic leukemia [CMML], acute myeloid leukemia [AML]) with an overall prevalence of approximately 75% and a median age of onset of roughly 20 years. Three major mutational types are encountered in GATA2-deficient patients: truncating mutations prior to ZF2, missense mutations within ZF2, and noncoding variants in the +9.5kb regulatory region of GATA2. Recurrent somatic lesions comprise monosomy 7 and trisomy 8 karyotypes and mutations in SETBP1 and ASXL1 genes. The high risk for progression to advanced myeloid neoplasia and life-threatening infectious complications guide decision-making towards timely stem cell transplantation.
DOI: 10.1053/j.seminhematol.2017.05.002
PubMed: 28637621
Affiliations:
- Allemagne, Royaume-Uni, États-Unis
- Bade-Wurtemberg, District de Karlsruhe, Washington (État)
- Heidelberg
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000131
- to stream PubMed, to step Curation: 000131
- to stream PubMed, to step Checkpoint: 000131
- to stream Ncbi, to step Merge: 009216
- to stream Ncbi, to step Curation: 009216
- to stream Ncbi, to step Checkpoint: 009216
- to stream Main, to step Merge: 000538
- to stream Main, to step Curation: 000538
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">GATA2 deficiency and related myeloid neoplasms.</title><author><name sortKey="Wlodarski, Marcin W" sort="Wlodarski, Marcin W" uniqKey="Wlodarski M" first="Marcin W" last="Wlodarski">Marcin W. Wlodarski</name><affiliation wicri:level="3"><nlm:affiliation>Department of Pediatrics and Adolescent Medicine, Division of Pediatric Hematology and Oncology; Medical Center; Faculty of Medicine, University of Freiburg, Germany; German Cancer Consortium (DKTK), Freiburg, Germany and German Cancer Research Center (DKFZ), Heidelberg, Germany. Electronic address: marcin.wlodarski@uniklinik-freiburg.de.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Pediatrics and Adolescent Medicine, Division of Pediatric Hematology and Oncology; Medical Center; Faculty of Medicine, University of Freiburg, Germany; German Cancer Consortium (DKTK), Freiburg, Germany and German Cancer Research Center (DKFZ), Heidelberg</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Karlsruhe</region><settlement type="city">Heidelberg</settlement></placeName></affiliation></author><author><name sortKey="Collin, Matthew" sort="Collin, Matthew" uniqKey="Collin M" first="Matthew" last="Collin">Matthew Collin</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom; Northern Centre for Bone Marrow Transplantation, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom; Northern Centre for Bone Marrow Transplantation, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne</wicri:regionArea><wicri:noRegion>Newcastle upon Tyne</wicri:noRegion></affiliation></author><author><name sortKey="Horwitz, Marshall S" sort="Horwitz, Marshall S" uniqKey="Horwitz M" first="Marshall S" last="Horwitz">Marshall S. Horwitz</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pathology, University of Washington School of Medicine, Seattle, WA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pathology, University of Washington School of Medicine, Seattle, WA</wicri:regionArea><placeName><region type="state">Washington (État)</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28637621</idno><idno type="pmid">28637621</idno><idno type="doi">10.1053/j.seminhematol.2017.05.002</idno><idno type="wicri:Area/PubMed/Corpus">000131</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000131</idno><idno type="wicri:Area/PubMed/Curation">000131</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000131</idno><idno type="wicri:Area/PubMed/Checkpoint">000131</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000131</idno><idno type="wicri:Area/Ncbi/Merge">009216</idno><idno type="wicri:Area/Ncbi/Curation">009216</idno><idno type="wicri:Area/Ncbi/Checkpoint">009216</idno><idno type="wicri:Area/Main/Merge">000538</idno><idno type="wicri:Area/Main/Curation">000538</idno><idno type="wicri:Area/Main/Exploration">000538</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">GATA2 deficiency and related myeloid neoplasms.</title><author><name sortKey="Wlodarski, Marcin W" sort="Wlodarski, Marcin W" uniqKey="Wlodarski M" first="Marcin W" last="Wlodarski">Marcin W. Wlodarski</name><affiliation wicri:level="3"><nlm:affiliation>Department of Pediatrics and Adolescent Medicine, Division of Pediatric Hematology and Oncology; Medical Center; Faculty of Medicine, University of Freiburg, Germany; German Cancer Consortium (DKTK), Freiburg, Germany and German Cancer Research Center (DKFZ), Heidelberg, Germany. Electronic address: marcin.wlodarski@uniklinik-freiburg.de.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Pediatrics and Adolescent Medicine, Division of Pediatric Hematology and Oncology; Medical Center; Faculty of Medicine, University of Freiburg, Germany; German Cancer Consortium (DKTK), Freiburg, Germany and German Cancer Research Center (DKFZ), Heidelberg</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Karlsruhe</region><settlement type="city">Heidelberg</settlement></placeName></affiliation></author><author><name sortKey="Collin, Matthew" sort="Collin, Matthew" uniqKey="Collin M" first="Matthew" last="Collin">Matthew Collin</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom; Northern Centre for Bone Marrow Transplantation, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom; Northern Centre for Bone Marrow Transplantation, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne</wicri:regionArea><wicri:noRegion>Newcastle upon Tyne</wicri:noRegion></affiliation></author><author><name sortKey="Horwitz, Marshall S" sort="Horwitz, Marshall S" uniqKey="Horwitz M" first="Marshall S" last="Horwitz">Marshall S. Horwitz</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pathology, University of Washington School of Medicine, Seattle, WA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pathology, University of Washington School of Medicine, Seattle, WA</wicri:regionArea><placeName><region type="state">Washington (État)</region></placeName></affiliation></author></analytic><series><title level="j">Seminars in hematology</title><idno type="eISSN">1532-8686</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The GATA2 gene codes for a hematopoietic transcription factor that through its two zinc fingers (ZF) can occupy GATA-DNA motifs in a countless number of genes. It is crucial for the proliferation and maintenance of hematopoietic stem cells. During the past 5 years, germline heterozygous mutations in GATA2 were reported in several hundred patients with various phenotypes ranging from mild cytopenia to severe immunodeficiency involving B cells, natural killer cells, CD4(+) cells, monocytes and dendritic cells (MonoMAC/DCML), and myeloid neoplasia. Some patients additionally show syndromic features such as congenital deafness and lymphedema (originally defining the Emberger syndrome) or pulmonary disease and vascular problems. The common clinical denominator in all reported cohorts is the propensity for myeloid neoplasia (myelodysplastic syndrome [MDS], myeloproliferative neoplasms [MPN], chronic myelomonocytic leukemia [CMML], acute myeloid leukemia [AML]) with an overall prevalence of approximately 75% and a median age of onset of roughly 20 years. Three major mutational types are encountered in GATA2-deficient patients: truncating mutations prior to ZF2, missense mutations within ZF2, and noncoding variants in the +9.5kb regulatory region of GATA2. Recurrent somatic lesions comprise monosomy 7 and trisomy 8 karyotypes and mutations in SETBP1 and ASXL1 genes. The high risk for progression to advanced myeloid neoplasia and life-threatening infectious complications guide decision-making towards timely stem cell transplantation.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Bade-Wurtemberg</li><li>District de Karlsruhe</li><li>Washington (État)</li></region><settlement><li>Heidelberg</li></settlement></list><tree><country name="Allemagne"><region name="Bade-Wurtemberg"><name sortKey="Wlodarski, Marcin W" sort="Wlodarski, Marcin W" uniqKey="Wlodarski M" first="Marcin W" last="Wlodarski">Marcin W. Wlodarski</name></region></country><country name="Royaume-Uni"><noRegion><name sortKey="Collin, Matthew" sort="Collin, Matthew" uniqKey="Collin M" first="Matthew" last="Collin">Matthew Collin</name></noRegion></country><country name="États-Unis"><region name="Washington (État)"><name sortKey="Horwitz, Marshall S" sort="Horwitz, Marshall S" uniqKey="Horwitz M" first="Marshall S" last="Horwitz">Marshall S. Horwitz</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000538 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000538 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:28637621
|texte= GATA2 deficiency and related myeloid neoplasms.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:28637621" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |